Last reviewed · How we verify
NCT07342738
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
EARLY_PHASE1 trial testing TCR-T cells in KRAS G12V in 25 participants. Not yet recruiting.
1 February 2028
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 1 February 2026 |
| Primary completion | 1 February 2028 |
| Estimated completion | 1 February 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- TCR-T cells
- Fludarabine (FLUDARABINE) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- KRAS G12V — all drugs for KRAS G12V →
- KRAS G12D — all drugs for KRAS G12D →
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, any sex, with KRAS G12V or KRAS G12D. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-arm, Multicenter, open-label clinical study aimed at evaluating the safety and efficacy of TCR-T injection in patients with advanced solid tumors induced by KRAS mutations.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07342738
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TCR-T cells
Trials testing the same drug.
- NCT03778814 — TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors · Phase 1 · recruiting
Other recruiting trials for KRAS G12V
Currently open trials in the same condition.
- NCT05631899 — CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors · Phase 1 · active not recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07342738 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07342738.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing